White House strikes new deals to lower prices on obesity drugs for some

By Sydney Lupkin

Published November 7, 2025 at 3:56 AM CST

Facebook
Twitter
LinkedIn
Email

The Trump administration struck deals with pharmaceutical companies Novo Nordisk and Eli Lilly to lower prices and copays for type 2 diabetes and obesity drugs --- but not everyone will qualify.

Facebook
Twitter
LinkedIn
Email

Sydney Lupkin

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

See stories by Sydney Lupkin